Scoop has an Ethical Paywall
$21m savings for migraine medicines
24 May, 2007
$21m savings for migraine medicines
People needing relief for migraine attacks will have a choice of fully funded treatments as a result of a new move by PHARMAC that will also save more than $20 million.
PHARMAC has listed generic sumatriptan tablets – which means that they will be fully funded for patients. At the same time, GlaxoSmithKline has agreed to lower the cost of its brand of the drug (Imigran), so it will continue to be fully funded as well.
PHARMAC Medical Director, Dr Peter Moodie, says the decision is good news for patients and the taxpayer.
“It is pleasing to be able to maintain access to the medicines that we fund while saving $21 million over the next five years.”
“Migraines impact on a number of New Zealanders and PHARMAC is pleased to be able to continue giving them access to a medicine they trust and to free up funds that we can use to purchase other medicines.”
ENDS
NZ Drug Foundation: Two New Studies Show A Concerning Increase In Drug Use And Availability
Emirates Team NZ: Emirates Team New Zealand Ranked #5 In Global Sports Technology Power List
Tātaki Auckland Unlimited: Discover The Treasures Of Tāmaki Makaurau - Making Māori Tourism Accessible To All
International Writers' Workshop NZ Inc: Ōtepoti Poets Top The Kathleen Grattan Prize For A Sequence Of Poems
NZ Amateur Sport Association: 22 Amendments Proposed For 2022 Act Lodged On 22 November
Auckland University of Technology: Reading Helps Children Face A Difficult Future